Hearing Loss and Congenital Symptomatic Cytomegalovirus Infection: A Case Report of Multidisciplinary Longitudinal Assessment and Intervention

Faye P. McCollister*
L. Clark Simpson†
Arthur J. Dahle‡
Robert F. Pass§
Karen B. Fowler∥
Catherine S. Amos∥
Thomas J. Boll∫

Abstract

More than 6000 children born annually in this country have hearing loss resulting from congenital cytomegalovirus (CMV) infection, the leading nonhereditary congenital cause of hearing loss in children. This exemplary congenital symptomatic CMV case focuses on the results of longitudinal audiologic, educational, medical, psychological, and visual evaluations and intervention. Decreased ocular motor control and visual acuity were observed as was bilateral deterioration of hearing from 3 days though 9 years of age. Treatment with dexamethasone and histamine resulted in almost complete reversal of the most recent progression of hearing loss in the left ear.

Key Words: Congenital cytomegalovirus (CMV) infection, hearing loss, immunosuppressant agents, multidisciplinary longitudinal assessment

The congenital cytomegalovirus (CMV) infection rate ranges from 0.5 to 2.4 percent (Starr et al, 1970; Hanshaw, 1971; Stagno et al, 1977; MacDonald and Tobin, 1978), with an average infection rate of 1 percent of all live births (U.S. National Center for Health Statistics, 1991). CMV is not only the most frequent congenital infection in humans, but is also the leading congenital nonhereditary cause of sensorineural hearing loss in children (Hanshaw, 1982; Hicks et al, 1993). Results from a study by S. Harris and colleagues (1984) suggest that congenital CMV is the single leading cause of childhood sensorineural hearing loss. Nonetheless, CMV hearing loss has been difficult to characterize because of differences in research protocols, subject groups, and individual subjects. From 1964, when Medearis first described the symptoms associated with CMV, reports suggest that about 60 percent of subjects with the CMV symptom complex, including hepatosplenomegaly, microcephaly, thrombocytopenia, and jaundice with direct hyperbilirubinemia, have hearing loss (Hanshaw, 1971; Stagno et al, 1977; Saigal et al, 1982; Bopanna et al, 1992). Additionally, congenital asymptomatic CMV, which occurs in over 90 percent of newborns with CMV infection, causes hearing loss over several years in as many as 15 percent of cases (Williamson et al, 1992). When these percentages are combined and applied to the annual birth rate of 4.1 million in the United States, more than 6000 children born each year experience sensorineural hearing loss as a result of congenital CMV infection (Hanshaw et al, 1976; Stagno et al, 1977; Saigal et al, 1982; Williamson et al, 1990, 1992; Bopanna et al, 1992). Hearing
loss continues to worsen or occurs later in life in approximately 75 to 80 percent of these subjects (Dahle et al, 1979; Stagno, 1990; Williamson et al, 1992).

Although treatment protocols for progressive or idiopathic sudden deafness frequently involve steroids (Wilson, 1980, 1986; Hall et al, 1993), treatment of CMV in humans has generally involved antiviral drugs rather than immune response-mediating drug therapies, and the antiviral drugs are usually not prescribed as a specific treatment for deafness (Reigstad et al, 1992; Attard-Montalto et al, 1993; Trang et al, 1993). Further, outcome studies of CMV treatment with antiviral drugs such as ganciclovir have not reported hearing loss reversal or hearing improvement in humans (Demmler, 1991). However, studies involving guinea pigs (GCMV) have suggested that the CMV damage to the auditory system may be partially immune-mediated (Harris et al, 1990). These studies have demonstrated that administration of cyclophosphamide for a 13-day period resulted in better preserved hearing, with experimental animals showing moderate hearing loss as opposed to profound hearing loss in the untreated control group (Darmstadt et al, 1990).

This case report summarizes multidisciplinary longitudinal evaluations and intervention data from the first decade of life of a subject with hearing loss and congenital symptomatic CMV infection. The subject, followed by the Perinatal Infectious Disease Project at The University of Alabama at Birmingham, was selected from a cohort of 78 subjects with hearing loss and congenital CMV infection. The report also describes treatment of hearing loss progression and subsequent improvement in hearing sensitivity.

CASE REPORT

The female subject was the product of a term pregnancy for a healthy, white 19-year-old with no pregnancy complications other than an upper respiratory infection with low-grade fever for 1 day during the fourth to fifth month of pregnancy. The subject had symptomatic manifestations of CMV in the neonatal nursery: facial petechiae, thrombocytopenia, hepatosplenomegaly, and jaundice with direct hyperbilirubinemia. A urine culture for CMV was positive. Meconium aspiration resulted in lung disease and supplemental oxygen was required. Hearing evaluation using auditory brainstem response (ABR) click stimuli was conducted at 3 days of age. Replicated waveforms at 20 dB nHL suggested normal hearing for each ear in the higher frequency range (1000–4000 Hz). When examined initially at 1 month of age by the project pediatrician, the subject was small, but alert and attentive. No petechiae were detected at this time; the platelet count had increased, but was still below normal, and hepatosplenomegaly was evident. By 7 months of age, the platelet count was normal and hepatosplenomegaly was no longer present. At the 1-year evaluation, the pediatrician noted that physical development was appropriate with the exception of increased muscle tone in the lower extremities, with toes often held in an abnormal position. The subject’s mother was concerned that the child had been delayed in sitting independently and was not walking without assistance. Results of the Alpern Boll Developmental Profile (Alpern et al, 1980) administered at the 1-year evaluation suggested normal intelligence, delayed motor development, and delayed communication development.

Psychological evaluation at 4 years, 2 months of age using the Leiter International Performance Scale (Arthur, 1952) revealed normal intellectual functioning. However, a developmental profile (Alpern et al, 1980) administered at the same time showed an 8-month delay in both motor and academic development and a 14-month delay in communication development. Psychological assessment at 7 years, 8 months of age indicated normal intellectual functioning. Achievement test scores indicated reading skills commensurate with IQ; however, arithmetic skill deficiencies were noted. Adequate motor speed was noted, but fine motor coordination was poor on the left side. Behavioral assessment revealed no significant problems. Visual perceptual skills had improved and, at the time of this testing, were within the expected range. Results of the Alpern Boll Developmental Profile (Alpern et al, 1980) showed motor development at 3 months above normal, academic development 5 months delayed, and communication development 21 months delayed. At 9 years of age, according to her teachers, the subject’s math and reading performance was at grade level.

Vision examination at 2 months indicated that the pupils were sluggishly reactive to light and that low hyperopia was present in each eye. Exotropia of the left eye at close range only was detected at age 4 years, 9 months. Because of alternating exotropia, home eye exercises were initiated at 5 years, 3 months of age. Visual acuity at that time was 20/20 for both distant and near ranges. At 6 years, 5 months of age, constant
left exotropia at distance and intermittent left exotropia at close range with poor ability to fuse were reported. Visual acuity was 20/25+ for each eye tested separately and 20/20 for both eyes tested simultaneously. The subject was fitted with eyeglasses at this time. At 8 years, 10 months of age, an increased amount of alternating exotropia and decreased visual acuity to 20/30+ aided were detected in each eye, and, at this time, the prescription strength of the subject's eyeglasses was increased.

Hearing

Serial audiologic evaluations (N = 35) performed from the age of 3 days, when hearing was normal, through 9 years provided documentation of prolonged bilateral deterioration of hearing (see Fig. 1). At the age of 2 months, air- and bone-conduction ABR results indicated mild bilateral sensorineural hearing loss. At approximately 4 months of age, ABR click test results for air and bone conduction were consistent with bilateral sensorineural hearing loss: mild to moderate in the left ear and profound in the right ear. At 6 months of age, the subject was fitted with a hearing aid in the left ear. During the next several months, she experienced numerous episodes of otitis media. Behavioral results obtained in sound field for the better ear (left) indicated hearing loss fluctuations between moderate and severe. The subject continued to have bouts of otitis media and was referred to an otolaryngologist, who inserted pressure equalization tubes at 1 year of age. Behavioral test results obtained in sound field following insertion of the tubes suggested moderate sensorineural loss of hearing. The subject was fitted with binaural aids at that time.

From 2 until 7 years of age, hearing loss was relatively stable bilaterally: profound in the right ear and moderate in the left ear. At 7 years of age, hearing loss increased to the severe range in the left ear.

At 8 years and 4 months of age, the subject complained that her hearing aid and auditory trainer were broken. Her teachers and parents certified that those amplification devices were functioning appropriately; however, the patient continued to complain of poor hearing and a constant fluttering sensation in the left ear. Her demeanor changed from happy and compliant to anxious. She was referred to her pediatrician, who diagnosed bilateral effusion with a mild infection in the left ear; an antibiotic and a decongestant were prescribed.

Ten days later, the subject complained of complete deafness in her left ear and of the continued fluttering sensation in that ear. When examined by an otolaryngologist, no evidence of middle ear fluid or infection was seen. Audiologic results confirmed that hearing had decreased to a profound loss in the left ear. The subject was hospitalized and received a CAT scan, which revealed no abnormalities. Intravenous histamine and dexamethasone were initiated and continued for 3 days. Upon dismissal from the hospital, audiologic test results continued to show bilateral profound loss of hearing. The subject began a regimen of oral dexamethasone (2 mg twice a day), histamine sublingual drops, cyclandelate tablets, and cimetidine. After 5 days, the subject reported better hearing in her left ear, and periodic audiologic monitoring documented gradual improvement in hearing sensitivity, as shown in Figure 2. Two weeks following initiation of medication, a 15 to 25-dB improvement in hearing thresholds for the 0.5- to 8-kHz range for the left ear was documented and the dosage of dexamethasone was decreased to 2 mg once a day for 1 week and then to 1 mg once a day for 1 week. The subject experienced weight gain and moodiness as a consequence of medication, so the dosage was further tapered to 0.5 mg every other day, with continued use of histamine drops. The subject's mother reported that the child's former personality and happy temperament had returned, though she...
experienced facial puffiness. The fluttering sensation in her left ear was no longer present. Dexamethasone was discontinued after 2½ months. Audiologic testing at 9 months from initial treatment revealed continuing substantial improvement in hearing without any medications. Audiologic results obtained at 16 months from initial treatment indicated stable levels despite some reported subjective fluctuations in hearing.

**DISCUSSION**

Studies have suggested that the pathologies causing hearing to deteriorate in CMV-infected inner ears include both the host's inflammatory response and the cytopathic effect of the virus (Keithley et al, 1989). Stagno and colleagues (1977) speculated that immune-mediated damage, including inflammation and edema of inner ear structures, might be as important or more important than viral damage. GPCMV studies lend further support to immune-mediated damage (Harris et al, 1984; Woolf et al, 1985). Of additional importance in GPCMV study is that viral reactivation did not occur with the use of the immunosuppressant cyclophosphamide. It appears also that cyclophosphamide can reach inflammatory cell infiltrates in inner ear structures. Darmstadt and colleagues (1990) speculated that because cyclophosphamide and prednisone are efficacious in other autoimmune disorders, their use in sensorineural hearing loss of viral origin could be appropriate. The antiviral agent ganciclovir, a virostatic drug that does not kill or otherwise eliminate CMV, but holds it in check until the drug is stopped, also has been proposed (Woolf et al, 1988). The drug has been approved for adult use, and trials with newborns have begun (Demmler, 1991).

Treating viral-related illnesses with immunosuppressant agents (ISAs) is not innovative. Infectious mononucleosis (Epstein-Barr virus), Bell's Palsy (herpes simplex virus), and Ramsay-Hunt syndrome (varicella zoster virus) are all examples of viral-mediated illnesses that respond to steroids. Theoretically, with any of these viruses, ISAs could cause viral reactivation and spread. Questions still remain regarding the risks of latent or persistent viral disease and side effects when using ISAs; these concerns mandate close monitoring (Keithley et al, 1989). Although treatment variables associated with each case must be assessed carefully, with attention given to possible benefits and particular risks, ISA treatment should be considered for CMV-related delayed onset/progressive sensorineural hearing loss, just as progression of sensorineural hearing loss in non-CMV cases is treated. If the loss is secondary to an autoimmune process, then ISAs should be beneficial. If inflammation can be halted before structural damage occurs, then hearing loss may be prevented. If the risk of viral reactivation is low, then treatment with these agents seems reasonable. It could, in fact, be speculated that, in the chronic situation, ISAs could make viral particles still present more accessible so that antiviral agents can more readily reach them. Combination therapy using antiviral agents with either corticosteroid or cyclophosphamide merits investigation.

As in cases with autoimmune hearing loss, hearing gain can be dramatic during a short period of time or may require months; therefore, treatment should not be discontinued prematurely (McCabe, 1979). There is probably a degree of urgency in initiation of therapy as a loss in hearing of recent onset is more likely to respond than one that occurred months or years earlier (Hicks and Wright, 1991). In this particular case, the most recent progression of sensorineural hearing loss was halted and reversed by the use of ISAs. This patient's hearing was
clearly progressive without therapy and showed
dramatic reversal of the recent drop with the use
of corticosteroid and vasodilator (dexametha-
sone and histamine).

Routine screening for congenital CMV, hear-
ing, and vision with multidisciplinary inter-
vention services resulted in improved outcome
for this patient. Intervention services were mod-
ified to accommodate needs as development and
sensory abilities changed. The various educa-
tional services for children with hearing loss
included a parent-infant program, a correspon-
dence course for parents, a self-contained class,
and finally a regular class with total main-
streaming. Audiologic services included early
baseline and frequent threshold monitoring,
hearing aids with maximum flexibility in power
and frequency response, as well as training in
communication methods that accommodated
changing hearing levels. Training provided to
teachers and parents regarding CMV and hear-
ing loss included information about changes in
behavior that could indicate deterioration of
hearing.

In contrast to the timely identification and
intervention for the symptomatic case described,
most children born with CMV infection do not
have overt symptoms during the first 3 weeks
of life and are not identified. Unfortunately,
after 3 weeks of age, they cannot be differenti-
ated from the 60 to 80 percent of the general pop-
ulation with postnatally acquired CMV, which
is generally inconsequential (Demmler, 1991).
Further, these children who acquire CMV post-
natally are not known to be at risk for early
onset, delayed onset, or progressive hearing
loss; vision abnormality; neurologic problems;
and/or learning difficulties. These complications
of congenital asymptomatic CMV infection are
frequently identified late and are usually man-
aged medically and educationally without knowl-
edge of the etiology.

Substantial effort is being put into research
for the establishment of an effective universal
newborn hearing screening program (National
Institutes of Health, 1993) and refinement of
the risk criteria for hearing loss (Joint Commit-
tee on Infant Hearing, 1991). Successful imple-
mentation of these efforts will reduce the average
age of identification for many infants who are deaf
or hard-of-hearing. However, neither of these
efforts will identify the 37,000 infants born an-
nually in this country with congenital asympto-
matic CMV infection who are at risk for early
onset, delayed onset, and/or progressive hearing
loss, as well as other disabling conditions.

Further, those who have or develop hearing loss
and are identified later cast doubt as to the
validity of hearing screening procedures. Approp-
riate monitoring at 2- to 6-month intervals for
progressive or delayed onset hearing loss in this
population is dependent on CMV identification,
and this can be accomplished only through
screening for CMV infection in newborns.
Although recommendations for routine screen-
ing of newborns for CMV have been made by
investigators and cost-efficient screening meth-
ods have been developed (Balcarek et al, 1993),
only a few infants are actually screened. When hear-
ing, vision, neurologic, and learning disabilities
resulting from congenital CMV infection are
enumerated, the magnitude of the problem and
the size of the population affected seem to war-
rant basic CMV screening and identification,
which would facilitate knowledgeable and timely
audiologic, visual, educational, and medical ser-
vice delivery for the children affected. Further,
identification of congenital CMV infection would
allow practitioners to not only use but also
expand the existing knowledge base regarding
multidisciplinary treatment and intervention
for children with congenital CMV infection.

Acknowledgment. This work was supported in part
by the National Institutes of Health, National Institute
of Child Health and Human Development (HD10699),
General Clinical Research Center (M01 RR0032), Deaf-
ness Research Foundation, the Civitan International
Research Center, and The University of Alabama Research
Grants Committee. The subject was evaluated while the
lead author was affiliated with the Civitan International
Research Center at the University of Alabama at Birm-
ingham. Appreciation is expressed to Jethlyn Potts and
Alexia Kartis for assistance in manuscript preparation.

REFERENCES

Alpern GD, Boll TJ, Shearer MS. (1980). Developmental
Profile II-Revised Edition. Aspen, CO: Psychological
Development Publications.

International Performance Scale. Los Angeles: Western
Psychological Services.

Attard-Montalto SP, English MC, Stimmmer L, Snodgrass
GJ. (1993). Ganciclovir treatment of congenital
cytomegalovirus infection: a report of two cases. Scand

Balcarek KB, Warren W, Smith RB, Lyon MB, Pass RF.
(1993). Neonatal screening for congenital cytomegalovirus
infection by detection of virus in saliva. J Infect Dis
167:1433-1436.


